Pfizer Files for Emergency Use From FDA

Don Tran
By Don Tran
November 21, 2020NTD News Today

In Phase 3 of clinical trials, Pfizer said it found that its vaccine, known as BNT162b2, was 95 percent effective in developing immunity to the CCP virus.

The drug company has submitted a request for emergency approval from the FDA, which could allow it to use the vaccine in high-risk populations in the United States.

FDA attorney Alan Minsk said it could be available by the end of the year, but he’s cautiously optimistic.

ntd newsletter icon
Sign up for NTD Daily
What you need to know, summarized in one email.
Stay informed with accurate news you can trust.
By registering for the newsletter, you agree to the Privacy Policy.